Editor's note: Seeking Alpha is proud to welcome Evan Urbanski as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.
Hims & Hers: The Undervalued Gem Poised For Growth
Summary
- As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month.
- Reports that the company has already started shipping out injections to subscribers.
- HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.
- Current revenue and EPS estimates don't factor in the addition of GLP-1 injections.
- Director at Hims, Christopher D. Payne, bought almost $2 million worth of stock, post GLP-1 announcement.
Recent graduate. Investing in companies with good growth prospects trading at low multiples.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of HIMS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
In the case HIMS fall from current prices, I will continue to purchase more shares.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.